发明名称 Liquid Factor VIII Formulations
摘要 The invention is directed to a liquid, aqueous formulation of coagulation Factor VIII, comprising a Factor VIII molecule, a calcium salt in a concentration of more than 10 mM, and a saccharide and/or polyol in a concentration of at least 100 mM, wherein the formulation has a pH from 5.5-7.5. The invention furthermore provides a method for optimising a liquid formulation of coagulation Factor VIII, the method comprising the steps of: (i) Providing one or more liquid formulations comprising Factor VIII to be tested; (ii) Adding a protein denaturant to said liquid formulations, and incubating the resulting solutions for a predetermined period of time; (iii) Analysing the incubated solutions of (ii) for the presence of dissociated Factor VIII; and (iv) Selecting one or more formulation(s) having a desired low level of dissociated Factor VIII.
申请公布号 US2016000884(A1) 申请公布日期 2016.01.07
申请号 US201314420564 申请日期 2013.08.13
申请人 Novo Nordisk A/S 发明人 Rischel Christian;Soerensen Hans Holmegaard;Jensen Michael Bech;Bjerg Thomas
分类号 A61K38/37;C12Q1/58;C12Q1/56;A61K38/38;C07K19/00 主分类号 A61K38/37
代理机构 代理人
主权项 1. A liquid, aqueous formulation of coagulation Factor VIII, comprising a Factor VIII molecule; a calcium salt in a concentration of more than 10 mM; and a saccharide and/or polyol in a concentration of at least 100 mM; wherein the formulation has a pH from 5.5-7.5.
地址 Bagsvaerd DK